Biofortuna

About:

Biofortuna develops a range of molecular diagnostic products using proprietary freeze-dried technology.

Top Investors: Foresight Group, Catapult Ventures, Enterprise Ventures, Merseyside Special Investment Fund

Description:

Biofortuna provides molecular diagnostics services. It manufactures HLA and ABO genotyping product families for the transplantation and haematology markets. The company is also developing antibody screening, genotyping and phenotyping products, software for genotyping applications, transplant monitoring, and platforms for clinical laboratories, research centers and point-of-care customers. In addition, Biofortuna Ltd. provides genotyping and custom assay development services. The company was incorporated in 2008 and is based in Liverpool, the United Kingdom.

Total Funding Amount:

$6.95M

Headquarters Location:

Liverpool, Liverpool, United Kingdom

Founded Date:

2008-01-01

Contact Email:

info(AT)biofortuna.com

Founders:

David Charvill, Mike Bunce

Number of Employees:

11-50

Last Funding Date:

2012-04-11

IPO Status:

Private

Industries: